Complex I Inhibition in Cultured Cells as Model for Parkinson’s Disease

  • Rainer Ortmann
  • Andreas Hein
  • Stefan Frentzel

Abstract

Parkinson’s disease (PD) is a common neurodegenerative disease characterized by the death of dopaminergic neurons in the substantia nigra (SN) pars compacta. The etiology of PD is largely unknown. The finding that l-methyl-4-phenyl-l,2,3,6 tetrahydropyridine (MPTP) induces parkinsonism in humans, primates and rodents and inhibits NADH: ubiquinone oxidoreductase (complex I) of the respiratory chain has directed PD research towards this enzyme (Nicklas et al., 1985). Among the biochemical abnormalities observed in the brains of PD patients is a defect in complex I (Schapira et al., 1990). In the brain, this deficiency is specific for the SN. It is, however, also found peripherally in platelets, fibroblasts and muscle of PD patients (Swerdlow et al., 1996). The resulting decrease in mitochondrial energy (ATP) production of SN neurons might directly induce programmed cell death (PCD, apoptosis) and/or contribute to an increased vulnerability of these neurons by neurotoxins or endogenous glutamate. Both mechanisms may thus contribute to the progression of PD. Restoration of the energy balance in complex I deficient dopaminergic neurons may therefore prevent the progression of PD.

Keywords

Dopamine Cyclosporin Melatonin NADH Succinate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Idziorek T., Estaquier J., De B.F., Ameisen J.C., 1995, YOPRO-1 permits cytofluorometric analysis of programmed cell death (apoptosis) without interfering with cell viability,J. Immunol. Methods 185: 249.PubMedCrossRefGoogle Scholar
  2. Mosman T., 1983, Rapid colorimetric assay for cellular growth and survival:application for proliferation and cytotoxicity assays,J. Immunol. Methods 65: 55.CrossRefGoogle Scholar
  3. Nicklas W. J., Vyas I., Heikkila R.E., 1985, Inhibition of NADH-linked oxidation in brain mitochondria by l-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, l-methyl-4-phenyl-1,2,5,6-tetrahydropyridine,Life Sci. 36: 2503.PubMedCrossRefGoogle Scholar
  4. Richter C, Schweizer M., Cossarizza A., Pranceschi C., 1996, Control of apoptosis by the cellular ATP level,FEBS Lett.378: 107.PubMedCrossRefGoogle Scholar
  5. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., & Marsden CD., 1990, Mitochondrial complex I deficiency in Parkinson’s disease,J. Neurochem.54: 823.PubMedCrossRefGoogle Scholar
  6. Swerdlow R.H., Parks J.K., Miller S.W., Tuttle J.B., Trimmer P.A., Sheehan J.P., Bennett J.P., Jr., Davis R.E., Parker W.D. Jr., 1996, Origin and functional consequences of the complex I defect in Parkinson’s disease,Ann. Neurol.40: 663.PubMedCrossRefGoogle Scholar
  7. Zamzami N., Marchetti P., Castedo M., Decaudin D., Macho A., Hirsch T., Susin S.A., Petit P.X., Mignotte B., Kroemer G., 1995, Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death,J. Exp. Med.182: 367.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2000

Authors and Affiliations

  • Rainer Ortmann
    • 1
  • Andreas Hein
    • 1
  • Stefan Frentzel
    • 1
  1. 1.NOVARTIS Pharma ResearchBaselSwitzerland

Personalised recommendations